About 250 therapeutists, pulmonologists and allergologists were present at this conference.

Megacom Company took part in this conference as a stand exhibition.

Also on the first day of the conference the reports on such products as Aerofillin and Cefodox were given.

Candidate of Medical Sciences, Polianskaya M.A. (F.G. Yanovsky Institute of Phtisiology and Pulmonology, Academy of Medical Sciences of Ukraine, Kiev) presented the results of the study which was carried out on the basis of the institute.

In this report the effectiveness and safety of Aerofillin and Neofillin were compared in therapy of patients with chronic obstructive pulmonary disease (stages 3, 4).

Aerofillin was more effective than the reference drug in treatment of patients with COPD, what was represented in the proved improvement of tolerance of physical activity (at the completion of the course of treatment the number of the meters walked by patients increased in fact in comparison with the initial data), improvement of the functionality – decrease of signs of lung hyperinflation (proved increase in respiratory capacity, decrease in intrathoracic gas volume, tendencies to lower airways resistance), increase in vital capacity of lungs, improvement in airways conductance (proved increase in FEV1, FVC); more expressed tendency to the reduction in dyspnea.

Aerofillin had a more expressed effect on inflammation, what became evident in proved increase in nitro blue tetrazolium reduction test (NBT-test) after the completion of the course of treatment in the group of patients, who took Aerofillin.

Aerofillin was better tolerated by the patients, no undesirable and side effects were observed during the use of this drug. Prof. Bagriy A.E. (Donetsk Medical University) reported about the results of a multicenter study “CENTER”, which was carried out in Vinnitsa, Zaporozhie, Donetsk.

The effectiveness and safety of Cefodox were studied in the stepwise therapy in patients with pneumonia. The preliminary microbiological analyses were not made.

In 93% of cases the therapy was effective. And only in 7% of cases the product was changed.